Sutro Biopharma (STRO) to Release Quarterly Earnings on Thursday

Sutro Biopharma (NASDAQ:STRO) will likely be posting its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Sutro Biopharma to post earnings of ($4.66) per share and revenue of $9.2630 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Sutro Biopharma Stock Up 8.2%

NASDAQ:STRO opened at $21.31 on Thursday. Sutro Biopharma has a 12-month low of $5.23 and a 12-month high of $21.42. The firm has a market capitalization of $181.35 million, a price-to-earnings ratio of -0.82 and a beta of 1.47. The stock’s 50 day moving average price is $15.07 and its two-hundred day moving average price is $11.27.

Hedge Funds Weigh In On Sutro Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STRO. Velan Capital Investment Management LP raised its stake in Sutro Biopharma by 2.0% during the third quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock worth $2,709,000 after acquiring an additional 60,000 shares in the last quarter. UBS Group AG increased its position in Sutro Biopharma by 14.0% during the 3rd quarter. UBS Group AG now owns 1,845,839 shares of the company’s stock worth $1,602,000 after purchasing an additional 226,955 shares in the last quarter. AQR Capital Management LLC lifted its stake in Sutro Biopharma by 1,052.8% in the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock valued at $859,000 after purchasing an additional 1,206,330 shares during the last quarter. Jane Street Group LLC bought a new position in Sutro Biopharma in the 2nd quarter valued at approximately $492,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Sutro Biopharma during the third quarter worth $387,000. 96.99% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on STRO. Wedbush restated a “neutral” rating and issued a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. Citizens Jmp raised shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price objective on the stock in a research report on Tuesday, January 20th. Wall Street Zen cut shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. HC Wainwright lifted their target price on shares of Sutro Biopharma to $10.00 and gave the stock a “neutral” rating in a report on Monday, December 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Monday, December 22nd. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Sutro Biopharma presently has an average rating of “Hold” and a consensus price target of $31.83.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.